Development of new extraction kits on various extraction platforms. Upgradation of existing products in view of attributes such as, but not limiting to performance improvement, cost reduction, new feature.
To have knowledge of ICH guidelines and other regional regulatory requirements including USFDA, EMA, NMPA, TGA, CADIFA and other global regulatory market.
The regulatory submissions to the FDA and EMA are supported by previously announced results from the Viti-Up studies evaluating the safety and efficacy of upadacitinib in patients with NSV.
Alembic Pharmaceuticals Limited has strengthened its US generics portfolio with the final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) covering Carbidopa, Levodopa and Entacapone Tablets.
Zydus Lifesciences has achieved a significant regulatory milestone as the U.S. Food and Drug Administration (USFDA) granted Orphan Drug Designation (ODD) to its novel molecule Desidustat for the treatment of Sickle Cell Disease (SCD). The designation highlights the growing recognition of the urgent need for new and effective therapies in this rare and challenging condition.
B.Pharmacy with experience or M.Pharma, Master Degree in Chemistry / Microbiology. Candidates having experience in testing of drugs will be given preference. The candidates should also have sound knowledge of computer operation.
PhD with a post-doctoral experience of 0-2 years. Applicants should have a PhD in Human Genetics, Genomics, Forensic Science, Molecular Biology, Bioinformatics, or a related discipline in Life Sciences.
Completed applications are invited from eligible persons to fill the Pharmacist in Government Medical College Hospital, Government Hospital and Primary Health Centers through Kallakurichi District Health Association